Skip to main content
Premium Trial:

Request an Annual Quote

Syapse, Genesis Research Partner to Offer Expanded Oncology Real-World Evidence Services

NEW YORK – Syapse and Genesis Research this week announced they would combine services to offer both real-world evidence analytics and health economics and outcomes research to pharma clients.

San Francisco-based Syapse develops software to support oncology drug discovery and development and Genesis, based in Hoboken, New Jersey, is a real-world evidence and health economics and outcomes research organization.

The partnership will focus on pharma clients developing biomarker-directed oncology treatments. Syapse clients will gain access to Genesis' health economics and outcomes research tools, such as strategic planning and value demonstration services. Genesis' pharma clients will also gain access to Syapse's real-world evidence platform to develop these drugs.

"The pharmaceutical leaders we work with increasingly see the value that real-world evidence can bring to the process of developing and launching new treatments that make meaningful differences in the lives of patients," Genesis CEO Frank Corvino said in a statement. "We're excited to partner with Syapse, who can offer our clients a holistic view of the patient journey through their capture of real-world data in the oncology space, where we've come to understand the unique and varied ways that cancer presents in individual patients, as well as the potential role that biomarkers can play in diagnosing and treating these diseases more effectively."

The companies will begin offering the services to oncology clients in the coming months.

Earlier this year, Syapse partnered with Illumina to study the uptake and actionability of comprehensive genomic profiling in community oncology health systems using its data aggregation platform. This year, the company has also partnered with AdventHealth Cancer Institute in Central Florida and Delaware health system Bayhealth.